Edgen Stock·Sep 28 2025, 17:35戻る
戻る
BridgeBio Pharma's Acoramidis Demonstrates Early and Sustained Cardiovascular Benefits for ATTR-CM Patients
Edgen Stock·Sep 28 2025, 17:35
[1] Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM[2] Acoramidis: Revolutionizing ATTR-CM Treatment with Cardiovascular Breakthroughs and Market Potential - AInvest[3] Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM | MarketScreener